Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994516 | 0.96 | GRM5 (0.53) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6921889 | 0.85 | GRM5 (0.49) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6922860 | 0.83 | GRM5 (0.41) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL16245221 | 0.82 | GRM5 (0.47) | GRM5L3MBTL1 | |
| SCHEMBL6923716 | 0.78 | LMNA (0.45) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6923279 | 0.77 | GRM5 (0.41) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL9994909 | 0.76 | L3MBTL1 (0.41) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL6921520 | 0.76 | L3MBTL1 (0.54) | TDP1L3MBTL1NPC1RAB9AKDM4E | |
| SCHEMBL9994522 | 0.75 | GRM5 (0.40) | GRM5TDP1L3MBTL1NPC1RAB9A | |
| SCHEMBL9995135 | 0.75 | ALDH1A1 (0.42) | GRM5TDP1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-09-18 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | GRM5, GRIK5, GRM2 | GRM5 1/4885TDP1 3528/4885L3MBTL1 4064/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | GRM5 1/4885TDP1 1917/4885L3MBTL1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.